Redesigning for Speed: Addressing Life Cycle Compression in Biopharma
Executive Summary:
The biopharmaceutical industry faces significant challenges as the commercial life cycles of drugs have dramatically compressed over the past two decades. This trend, known as 'asset life cycle compression', involves a reduction in the time available to capture value from a product and the overall value that can be derived from it. This phenomenon is primarily driven by several key factors:
- Increased Competitive Intensity: More assets entering the market faster, influenced by the "herding" effect where drug development efforts concentrate on previously successful targets.
- Rapidly Evolving Clinical Practice: Ongoing innovation leads to quicker replacement of current standards of care with improved therapies.
- Policy and Payer Pressures: Net price deflation across the industry, exacerbated by recent U.S. policy changes like mandatory rebates and inflation penalties, and international pricing reforms tightening access.
- Advent of Biosimilar Interchangeability: Accelerating biosimilar adoption, particularly in Europe and the U.S., leading to a significant loss of exclusivity.
Evolution of Asset Life Cycles:
- Data Source: McKinsey's analysis of the top 36 biopharmaceutical companies' drug launches since 2001 reveals a marked decrease in the average time required for assets to accumulate 50% of their lifetime sales. This gap widens to 35 months when considering the time to capture 80% of lifetime sales.
- Impact Variability: The impact of life cycle compression varies between small-molecule products and biologics, as well as between single- and multi-indication assets.
- Portfolio Shifts: Portfolio composition has shifted significantly, with a notable increase in the proportion of single-indication small-molecule assets.
Forces Driving Life Cycle Compression:
- Increasing Competitive Intensity: More assets entering the market faster, influenced by the herding effect.
- Rapidly Evolving Clinical Practice: Continuous innovation replacing standard of care with improved therapies.
- Policy and Payer Pressures: Industry-wide deflation in net prices, exacerbated by recent U.S. policy changes and international pricing reforms.
- Biosimilar Interchangeability: Accelerated biosimilar adoption leading to loss of exclusivity.
Methodology:
- Analysis Basis: Data from Evaluate Omnium, providing insights into past, current, and projected sales by asset.
- Data Access: Data was accessed in March 2023, encompassing assets from the top 36 companies launched between 2001-2005 and 2021-2025.
- Sales Curve Analysis: Plotted revenue curves over the life cycle of assets to assess sales capture percentages annually.
Key Findings:
- Compressed Life Cycles: Notably, single-indication small-molecule assets have seen less pronounced life cycle compression compared to biologics and multi-indication small-molecule assets.
- Industry-Wide Effects: Driven by shifts in portfolio composition, with a significant change in the proportion of single-indication small-molecule assets from 66% in 2001-2005 to 30% in 2021-2025.
Recommendations for Biopharma Companies:
- Strategic Portfolio Management: Adjust portfolios to capitalize on opportunities while mitigating risks associated with life cycle compression.
- Speed and Agility: Enhance operational flexibility and decision-making processes to respond swiftly to market changes.
- Innovation Focus: Invest in continuous innovation to maintain competitive advantage and capture value from enhanced therapies before they are replaced.
- Pricing and Policy Adaptation: Develop strategies to navigate regulatory and payer pressures, focusing on sustainable pricing models and compliance with new legislative frameworks.
